Radio Vive! Salamanca welcomes Sara Cuadrado‑Castaño, the founder, CEO and Principal Investigator at ViroFend Therapeutics S.L., for a lively conversation about her latest antiviral research and the company’s mission to outsmart emerging pathogens.
Read more
One of the most important findings in cancer research in the past two decades is that tumors can create force field-like protection against the immune system. A new study has identified a way to break through that force field to improve cancer treatment, by taking advantage of a virus that can specifically infect cancer cells.
Read more
Salamanca-born researcher and doctor Sara Cuadrado-Castaño will be the announcer of the 2025 Salamanca Fairs and Festivals in recognition of her outstanding professional career in scientific research, as well as her commitment to disseminating knowledge and promoting Salamanca's talent nationally and internationally. Sara Cuadrado-Castaño has unquestionable international prestige, as well as a long and recognized track record in the fight against cancer.
Read more
Viruses are particles that infect or enter our cells and then use the cell’s genetic machinery to make copies of themselves and subsequently spread to surrounding uninfected cells. Infection by certain viruses has been implicated in the development of certain cancers, such as the hepatitis B virus (HBV) in liver cancer and the human papilloma virus (HPV) in cervical cancer and head and neck cancer.
Read more
The search for more effective and safer therapies remains a fundamental challenge in oncology. For the first time, this research led by Sara Cuadrado-Castaño demonstrates the therapeutic potential of certain avulaviruses other than Newcastle Disease Virus (NDV).
Read moreViroFend Therapeutics S.L. is a biopharmaceutical company focused on virus-driven immunotherapy for cancer, headquartered in Spain with global research collaborations.
©2024–2025 ViroFend Therapeutics S.L.
